UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 48

Sortiert nach

Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer

Annals of oncology, 2018-01, Vol.29 (1), p.139-144

2018

Volltextzugriff (PDF)

Systemic chemotherapy and surgical cytoreduction for poorly differentiated and signet ring cell adenocarcinomas of the appendix

Annals of oncology, 2012-03, Vol.23 (3), p.652-658

2012

Volltextzugriff (PDF)

Prognostic factors after resection of colorectal liver metastases following preoperative second-line chemotherapy: Impact of RAS mutations

European journal of surgical oncology, 2016-09, Vol.42 (9), p.1378-1384

2016

Volltextzugriff (PDF)

High prevalence of mutantKRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients

Annals of oncology, 2017-04, Vol.28 (4), p.741-747

2017

Volltextzugriff (PDF)

Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142

Annals of oncology, 2022-10, Vol.33 (10), p.1052-1060

2022

Volltextzugriff (PDF)

Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H)

Annals of oncology, 2014-05, Vol.25 (5), p.1032-1038

2014

Volltextzugriff (PDF)

JSCO—ESMO—ASCO—JSMO—TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions

Annals of oncology, 2020-07, Vol.31 (7), p.861-872

2020

Volltextzugriff (PDF)

Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge

Annals of oncology, 2019-02, Vol.30 (2), p.243-249

2019

Volltextzugriff (PDF)

Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment

Annals of oncology, 2015-04, Vol.26 (4), p.731-736

2015

Volltextzugriff (PDF)

631P Using the unique somatic mutation profile of POLE loss of proof-reading mutation helps in selection of patients who may benefit from immunotherapy

Annals of oncology, 2023-10, Vol.34, p.S448-S449

2023

Volltextzugriff (PDF)

Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: A single‐center, open‐label, phase 2 study

Cancer, 2017-03, Vol.123 (6), p.1011-1017

2017

Volltextzugriff (PDF)

190P Quantitative serum tumor markers (CEA, CA19-9, and CA-125) are independently predictive of survival in patients with appendiceal adenocarcinoma

Annals of oncology, 2023-10, Vol.34, p.S258-S258

2023

Volltextzugriff (PDF)

628P Immunotherapy in mismatch repair-deficient metastatic colorectal cancer: Long-term outcome and novel predictive markers

Annals of oncology, 2023-10, Vol.34, p.S447-S447

2023

Volltextzugriff (PDF)

91P Liquid biopsy for detection of minimal residual disease after liver metastasectomy in stage IV colorectal cancer

Annals of oncology, 2021-09, Vol.32, p.S395-S396

2021

Volltextzugriff (PDF)

Defining the subset of mutations in polymerase epsilon (POLE) associated with loss-of-proofreading (LOP) functionality

Annals of oncology, 2024-07, Vol.35 (7), p.678-680

2024

Volltextzugriff (PDF)

On the underreporting of health-related quality of life and regulatory approval

Annals of oncology, 2019-04, Vol.30 (4), p.657-658

2019

Volltextzugriff (PDF)

1631P Phase I study of endoscopic ultrasound (EUS)-guided NBTXR3 delivery activated by radiotherapy (RT) for locally advanced or borderline resectable pancreatic cancer (LAPC or BRPC)

Annals of oncology, 2023-10, Vol.34, p.S903-S903

2023

Volltextzugriff (PDF)

Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer

Annals of oncology, 2024-07, Vol.35 (7), p.643-655

2024

Volltextzugriff (PDF)

227P Clinical outcomes and molecular characterization of appendiceal goblet cell adenocarcinoma in 414 patients

Annals of oncology, 2024-06, Vol.35, p.S98-S98

2024

Volltextzugriff (PDF)

Selective registration of non-primary endpoints in randomized clinical trials in oncology: a comparison of endpoint reporting between clinical trial protocols and US national clinical trial registration

Annals of oncology, 2016-10, Vol.27, p.vi101-vi101

2016

Volltextzugriff (PDF)

Clinicopathologic characteristics and gene expression analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal cancer

Annals of oncology, 2014-10, Vol.25 (10), p.2008-2014

2014

Volltextzugriff (PDF)

1758O Neoadjuvant pembrolizumab in localized/locally advanced solid tumors with mismatch repair deficiency

Annals of oncology, 2021-09, Vol.32, p.S1210-S1210

2021

Volltextzugriff (PDF)

1004P Initial results from a phase I study of Nous-209, an off-the-shelf viral vectored immunotherapy encoding 209 shared frame shift peptide neoantigens, with pembrolizumab, for the treatment of tumors with a deficiency in mismatch repair/microsatellite instability

Annals of oncology, 2021-09, Vol.32, p.S850-S850

2021

Volltextzugriff (PDF)

Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials

Annals of oncology, 2016-06, Vol.27 (6), p.1068-1074

2016

Volltextzugriff (PDF)

A retrospective study of ampullary adenocarcinomas: overall survival and responsiveness to fluoropyrimidine-based chemotherapy

Annals of oncology, 2013-09, Vol.24 (9), p.2349-2353

2013

Volltextzugriff (PDF)

1 – 25 von 48

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(47)
Mit Volltextzugriff
(47)

Publikationsform

Artikel
(48)

Sprache

Englisch
(48)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Science & Technology
(30)
Life Sciences & Biomedicine
(19)
Oncology
(16)
Humans
(15)
Female
(12)
Male
(12)
Technology
(11)
Middle Aged
(10)
Adult
(9)
Aged
(8)
Original
(8)
Biological And Medical Sciences
(7)
Colorectal Cancer
(7)
Colorectal Neoplasms - Genetics
(7)
Colorectal Neoplasms - Pathology
(7)
Instruments & Instrumentation
(7)
Medical Sciences
(6)
Aged, 80 And Over
(5)
Antineoplastic Agents
(5)
Instrumentation Related To Nuclear Science And Technology
(5)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer

Systemic chemotherapy and surgical cytoreduction for poorly differentiated and signet ring cell adenocarcinomas of the appendix

Prognostic factors after resection of colorectal liver metastases following preoperative second-line chemotherapy: Impact of RAS mutations

High prevalence of mutantKRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients

Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142

Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H)

JSCO—ESMO—ASCO—JSMO—TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions

Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge

Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment

631P Using the unique somatic mutation profile of POLE loss of proof-reading mutation helps in selection of patients who may benefit from immunotherapy

Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: A single‐center, open‐label, phase 2 study

190P Quantitative serum tumor markers (CEA, CA19-9, and CA-125) are independently predictive of survival in patients with appendiceal adenocarcinoma

628P Immunotherapy in mismatch repair-deficient metastatic colorectal cancer: Long-term outcome and novel predictive markers

91P Liquid biopsy for detection of minimal residual disease after liver metastasectomy in stage IV colorectal cancer

Defining the subset of mutations in polymerase epsilon (POLE) associated with loss-of-proofreading (LOP) functionality

On the underreporting of health-related quality of life and regulatory approval

1631P Phase I study of endoscopic ultrasound (EUS)-guided NBTXR3 delivery activated by radiotherapy (RT) for locally advanced or borderline resectable pancreatic cancer (LAPC or BRPC)

Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer

227P Clinical outcomes and molecular characterization of appendiceal goblet cell adenocarcinoma in 414 patients

Selective registration of non-primary endpoints in randomized clinical trials in oncology: a comparison of endpoint reporting between clinical trial protocols and US national clinical trial registration

Clinicopathologic characteristics and gene expression analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal cancer

1758O Neoadjuvant pembrolizumab in localized/locally advanced solid tumors with mismatch repair deficiency

1004P Initial results from a phase I study of Nous-209, an off-the-shelf viral vectored immunotherapy encoding 209 shared frame shift peptide neoantigens, with pembrolizumab, for the treatment of tumors with a deficiency in mismatch repair/microsatellite instability

Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials

A retrospective study of ampullary adenocarcinomas: overall survival and responsiveness to fluoropyrimidine-based chemotherapy

Suchergebnisse filtern